Irene Virgolini

13.7k total citations · 3 hit papers
314 papers, 9.1k citations indexed

About

Irene Virgolini is a scholar working on Epidemiology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Irene Virgolini has authored 314 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Epidemiology, 107 papers in Oncology and 98 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Irene Virgolini's work include Neuroendocrine Tumor Research Advances (111 papers), Radiopharmaceutical Chemistry and Applications (75 papers) and Lung Cancer Research Studies (62 papers). Irene Virgolini is often cited by papers focused on Neuroendocrine Tumor Research Advances (111 papers), Radiopharmaceutical Chemistry and Applications (75 papers) and Lung Cancer Research Studies (62 papers). Irene Virgolini collaborates with scholars based in Austria, Germany and Italy. Irene Virgolini's co-authors include Clemens Decristoforo, Christian Uprimny, Dorota Kendler, Michael Gabriel, Elisabeth von Guggenberg, P. Angelberger, Reto Bale, Georg Dobrozemsky, Stefano Fanti and Daniel Putzer and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Irene Virgolini

302 papers receiving 8.9k citations

Hit Papers

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: C... 2007 2026 2013 2019 2007 2017 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
    2007 746 citations Michael Gabriel, Clemens Decristoforo et al. profile →
  2. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA
    2017 310 citations Irene Virgolini, Clemens Decristoforo et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
  3. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour
    2017 263 citations Christian Uprimny, Alexander Kroiss et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Irene Virgolini Austria 47 3.7k 3.5k 3.4k 2.6k 2.0k 314 9.1k
Marion de Jong Netherlands 60 6.9k 1.9× 6.4k 1.9× 6.2k 1.8× 3.6k 1.4× 1.9k 0.9× 246 13.5k
E. P. Krenning Netherlands 58 8.4k 2.3× 6.7k 1.9× 2.9k 0.9× 5.2k 2.0× 988 0.5× 168 12.7k
Anders Sundin Sweden 51 6.1k 1.7× 5.5k 1.6× 1.9k 0.6× 4.1k 1.6× 871 0.4× 216 9.3k
Stanley J. Goldsmith United States 52 1.3k 0.3× 2.4k 0.7× 4.5k 1.3× 950 0.4× 3.3k 1.7× 223 9.2k
P Farah Lebanon 5 2.2k 0.6× 1.2k 0.4× 1.3k 0.4× 1.8k 0.7× 2.0k 1.0× 8 10.2k
Yaning Chen China 14 2.2k 0.6× 1.4k 0.4× 1.4k 0.4× 1.8k 0.7× 2.1k 1.0× 40 11.0k
David Schiff United States 69 2.7k 0.7× 2.8k 0.8× 1.7k 0.5× 3.3k 1.3× 3.8k 1.9× 373 16.9k
Charles J. Vecht Netherlands 46 2.2k 0.6× 1.7k 0.5× 1.1k 0.3× 1.9k 0.7× 3.6k 1.8× 105 10.3k
Michael Glantz United States 49 1.4k 0.4× 2.4k 0.7× 1.0k 0.3× 1.7k 0.6× 3.8k 1.9× 183 9.0k
Larry K. Kvols United States 63 10.2k 2.8× 9.2k 2.6× 1.4k 0.4× 7.3k 2.8× 1.3k 0.7× 225 13.8k

Countries citing papers authored by Irene Virgolini

Since Specialization
Citations

This map shows the geographic impact of Irene Virgolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene Virgolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene Virgolini more than expected).

Fields of papers citing papers by Irene Virgolini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irene Virgolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene Virgolini. The network helps show where Irene Virgolini may publish in the future.

Co-authorship network of co-authors of Irene Virgolini

This figure shows the co-authorship network connecting the top 25 collaborators of Irene Virgolini. A scholar is included among the top collaborators of Irene Virgolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irene Virgolini. Irene Virgolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Santo, Giulia, Gianpaolo di Santo, Francesco Cicone, & Irene Virgolini. (2025). Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. Journal of Neuroendocrinology. 37(3). e70013–e70013. 4 indexed citations
2.
3.
Santo, Gianpaolo di, et al.. (2025). Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 53(3). 1927–1938. 1 indexed citations
4.
Hoffmann, Manuela A., Çiğdem Soydal, Irene Virgolini, et al.. (2025). Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence—A Systematic Review and Meta-Analysis. Cancers. 17(5). 841–841. 1 indexed citations
5.
Defrancesco, Michaela, Elke R. Gizewski, Stephanie Mangesius, et al.. (2024). Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population. BJPsych Open. 10(5). e160–e160. 4 indexed citations
6.
Eyben, Finn Edler von, Irene Virgolini, & Richard P. Baum. (2024). Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer. Cancers. 16(14). 2520–2520. 1 indexed citations
7.
Santo, Giulia, Gianpaolo di Santo, Bettina Zelger, & Irene Virgolini. (2024). Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy. Nuklearmedizin - NuclearMedicine. 63(3). 219–220. 1 indexed citations
8.
Burkert, Francesco, Lukas Niederreiter, Wolfgang Dichtl, et al.. (2021). Case report of a COVID-19-associated myocardial infarction with no obstructive coronary arteries: the mystery of the phantom embolus or local endothelitis. European Heart Journal - Case Reports. 5(2). ytaa521–ytaa521. 12 indexed citations
9.
Nilica, Bernhard, et al.. (2021). Personalized Thera(g)nostic Approach in Patients with Paraganglioma: Peptide Receptor Radionuclide Therapy. 6(1). 1 indexed citations
10.
Uprimny, Christian, et al.. (2020). Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 48(3). 935–936. 20 indexed citations
11.
Summer, Dominik, Christine Rangger, Roland Haubner, et al.. (2018). DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. Journal of Nuclear Medicine. 60(7). 1010–1016. 49 indexed citations
12.
Eyben, Finn Edler von, Giandomenico Roviello, Timo Kiljunen, et al.. (2017). Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. European Journal of Nuclear Medicine and Molecular Imaging. 45(3). 496–508. 136 indexed citations
13.
Henninger, Benjamin, Daniel Putzer, Dorota Kendler, et al.. (2012). Diagnostic Value of Software-Based Image Fusion of Computed Tomography and F18-FDG PET Scans in Patients with Malignant Lymphoma. The Scientific World JOURNAL. 2012. 1–9. 1 indexed citations
14.
Gabriel, Michael, Clemens Decristoforo, Ewald Wöll, et al.. (2011). [ 99m Tc]Demotensin VI: Biodistribution and Initial Clinical Results in Tumor Patients of a Pilot/Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 26(5). 557–563. 13 indexed citations
15.
Mansi, Luigi & Irene Virgolini. (2011). Diagnosis and therapy are walking together on radiopeptides’ avenue. European Journal of Nuclear Medicine and Molecular Imaging. 38(4). 605–612. 13 indexed citations
16.
Decristoforo, Clemens, Janette Carlsen, Marco Rupprich, et al.. (2008). 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression. European Journal of Nuclear Medicine and Molecular Imaging. 35(8). 1507–1515. 133 indexed citations
17.
Li, Mei, Tatjana Traub‐Weidinger, P. Angelberger, et al.. (2003). 111 In-DOTA-dPhe 1 -Tyr 3 -octreotide, 111 In-DOTA-lanreotide and 67 Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging. 30(8). 1087–1095. 8 indexed citations
18.
Virgolini, Irene, et al.. (1991). Quantification of human hepatic binding protein (HBP) via 99mTc-galactosyl-neoglycoalbumin (NGA) liver scintigraphy.. PubMed. 103(15). 458–61. 3 indexed citations
19.
Virgolini, Irene, et al.. (1989). Prostaglandin-Interaktion in der menschlichen Leber. Journal of Molecular Medicine. 67(24). 1229–1235. 1 indexed citations
20.
Sinzinger, H & Irene Virgolini. (1989). [Do passive smokers have an increased risk of thrombosis?].. PubMed. 101(20). 694–8. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marion de Jong Breakdown of academic impact, for papers by E. P. Krenning Breakdown of academic impact, for papers by Anders Sundin Breakdown of academic impact, for papers by Stanley J. Goldsmith Breakdown of academic impact, for papers by P Farah Breakdown of academic impact, for papers by Yaning Chen Breakdown of academic impact, for papers by David Schiff Breakdown of academic impact, for papers by Charles J. Vecht Breakdown of academic impact, for papers by Michael Glantz Breakdown of academic impact, for papers by Larry K. Kvols
Rankless by CCL
2026